Swiss National Bank lifted its position in shares of R1 RCM Inc (NASDAQ:RCM) by 3.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 171,700 shares of the healthcare provider’s stock after purchasing an additional 5,900 shares during the quarter. Swiss National Bank owned about 0.15% of R1 RCM worth $2,229,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of RCM. Metropolitan Life Insurance Co NY raised its stake in shares of R1 RCM by 4.2% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 34,464 shares of the healthcare provider’s stock worth $308,000 after purchasing an additional 1,379 shares in the last quarter. Rhumbline Advisers grew its holdings in R1 RCM by 1.7% in the 4th quarter. Rhumbline Advisers now owns 140,299 shares of the healthcare provider’s stock valued at $1,821,000 after buying an additional 2,412 shares during the last quarter. Virtu Financial LLC grew its holdings in R1 RCM by 23.4% in the 4th quarter. Virtu Financial LLC now owns 15,317 shares of the healthcare provider’s stock valued at $199,000 after buying an additional 2,900 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in R1 RCM in the 4th quarter valued at approximately $43,000. Finally, FNY Investment Advisers LLC acquired a new stake in R1 RCM in the 4th quarter valued at approximately $45,000. Institutional investors and hedge funds own 73.69% of the company’s stock.
A number of analysts have issued reports on RCM shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $17.00 target price (up previously from $15.00) on shares of R1 RCM in a report on Tuesday, January 21st. BidaskClub upgraded R1 RCM from a “sell” rating to a “hold” rating in a research report on Friday, February 14th. Dougherty & Co assumed coverage on R1 RCM in a research report on Friday, January 10th. They set a “buy” rating and a $15.00 target price for the company. Zacks Investment Research raised R1 RCM from a “sell” rating to a “hold” rating in a research note on Wednesday, February 26th. Finally, KeyCorp lifted their price objective on R1 RCM from $14.00 to $15.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. R1 RCM has a consensus rating of “Buy” and an average target price of $14.20.
NASDAQ:RCM traded up $0.32 on Wednesday, reaching $12.68. The company’s stock had a trading volume of 9,349 shares, compared to its average volume of 883,205. R1 RCM Inc has a 1-year low of $8.77 and a 1-year high of $13.99. The company has a debt-to-equity ratio of 19.69, a quick ratio of 0.93 and a current ratio of 0.93. The firm has a market cap of $1.44 billion, a PE ratio of -115.76, a PEG ratio of 2.99 and a beta of 0.09. The business’s 50-day moving average price is $13.11 and its two-hundred day moving average price is $11.85.
R1 RCM (NASDAQ:RCM) last posted its earnings results on Thursday, February 20th. The healthcare provider reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.03). R1 RCM had a net margin of 1.01% and a return on equity of 116.79%. The business had revenue of $314.00 million during the quarter, compared to analyst estimates of $318.36 million. During the same period in the previous year, the firm posted ($0.10) earnings per share. The firm’s revenue was up 19.4% on a year-over-year basis. As a group, sell-side analysts expect that R1 RCM Inc will post 0.38 EPS for the current year.
About R1 RCM
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.